Details:
Rapid oral absorption of BNC210, a selective negative allosteric modulator of α7 nicotinic acetylcholine receptor used as novel tablet formulation potentially well-suited for acute treatment of anxiety in patients with Social Anxiety Disorder.
Lead Product(s): BNC210
Therapeutic Area: Psychiatry/Psychology Product Name: BNC210
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2021